Motixafortide
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
WBC Growth Factors: ASCO Guideline Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 25, 2026
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.
Journal: The oncologist
Published: September 05, 2025
A human iPSC-based neural spheroid platform for modelling glioblastoma infiltration using high-content imaging.
Journal: Scientific reports
Published: September 04, 2025
Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma.
Journal: Biomedical chromatography : BMC
Published: February 23, 2025
Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024.
Journal: Expert opinion on therapeutic patents
Published: February 10, 2025
Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: February 05, 2025
FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond.
Journal: Journal of peptide science : an official publication of the European Peptide Society
Published: April 26, 2024
A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: April 17, 2024
2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 20, 2024
CXCR4 as a therapeutic target in acute myeloid leukemia.
Journal: Leukemia
Published: January 11, 2024
Last Updated: 04/28/2026